MedTrace Logo

Travacom Post Marketing Surveillance Study

NCT01510132 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-10-18

No results posted yet for this study

Summary

The purpose of this multi-center, open label, single arm, post-marketing surveillance study is to assess the safety of Travacom in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other intraocular pressure-lowering (IOP) medication and when use of Travacom is considered appropriate.

Conditions

Interventions

DRUG

Travoprost/timolol fixed combination (Travacom)

Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01510132 on ClinicalTrials.gov